Last reviewed · How we verify

prolotherapy solution of 20% dextrose

Hadassah Medical Organization · FDA-approved active Small molecule

A 20% dextrose solution injected into damaged connective tissues stimulates a local inflammatory response that promotes tissue repair and regeneration.

A 20% dextrose solution injected into damaged connective tissues stimulates a local inflammatory response that promotes tissue repair and regeneration. Used for Chronic musculoskeletal pain from ligamentous laxity, Tendon injuries, Joint instability.

At a glance

Generic nameprolotherapy solution of 20% dextrose
Also known asDextrose 20% solution
SponsorHadassah Medical Organization
Drug classRegenerative medicine agent
ModalitySmall molecule
Therapeutic areaOrthopedics / Musculoskeletal
PhaseFDA-approved

Mechanism of action

Prolotherapy (proliferative therapy) works by inducing controlled inflammation at the injection site, which triggers the body's natural healing cascade. The hypertonic dextrose solution causes osmotic stress and irritation to ligaments, tendons, and other connective tissues, activating fibroblasts and promoting collagen deposition and tissue strengthening. This mechanism is intended to stabilize joints and reduce pain from chronic ligamentous laxity or tendon injuries.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: